Immuneering Launches Pancreatic Cancer Advisory Board
December 19, 2024 08:00 ET
|
Immuneering Corporation
Immuneering Launches Pancreatic Cancer Advisory Board
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma
December 12, 2024 08:00 ET
|
Immuneering Corporation
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients
September 12, 2024 16:05 ET
|
Immuneering Corporation
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line
Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 06, 2024 16:05 ET
|
Immuneering Corporation
Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
Immuneering to Present at the Jefferies Global Healthcare Conference
May 29, 2024 16:05 ET
|
Immuneering Corporation
Immuneering to Present at the Jefferies Global Healthcare Conference
Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline
April 18, 2023 09:00 ET
|
Immuneering Corporation
Data presented at AACR Annual Meeting support IMM-1-104's potential to address a broad population of patients with RAS mutant tumorsIMM-1-104 well tolerated with no dose limiting toxicities (DLTs) or...
Immuneering Announces Participation in March Investor Conferences
February 28, 2023 08:00 ET
|
Immuneering Corporation
CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an...
Immuneering to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates
February 27, 2023 08:00 ET
|
Immuneering Corporation
CAMBRIDGE, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an...